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 Topoisomerase II (TOP II) is a cellular enzyme responsible for solving 
topological problems of double-stranded DNA. Alpha and beta isoforms of TOP II are 
different gene products having similar catalytic activities. The expression of TOP IIα is 
cell-cycle dependent, peaking in G2/M phase, while TOP II isoform is expressed 
constitutively throughout the cell cycle. It is therefore present also in non-proliferating 
differentiated cells. Anthracycline antibiotics are an old class of anticancer drugs, 
belonging to TOP II poisons. Although their clinical usefulness is high, the incidence of 
side effects (especially myelotoxicity and cardiotoxicity) may limit the therapy. The key 
role of TOP II inhibition, which is present also in cardiomyocytes, has been increasingly 
discussed. Dexrazoxane, the only clinically used cardioprotective, leads to depletion of 
TOP II in cardiomyocytes, which may explain its cardioprotection. Although TOP II 
was previously shown to be dispensable for cellular proliferation, its possible effects on 
the sensitivity to various antineoplastic agents is not known. 
 Therefore, practical aim of this thesis was to describe the properties of a HL-60 
human promyelocytic leukaemia cell lines mutated for TOP II. The cells with both, one, 
or no functional copies of TOP II gene were previously developed by the CRISPR-Cas9 
technology. First, we studied these cell lines regarding the TOP IIα and TOP II mRNA 
and protein expression (by RT-qPCR and immunoblotting, respectively), and then 
regarding their sensitivity to daunorubicin and dexrazoxane. 
  
